Results 51 to 60 of about 8,117 (271)

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke, Edris Mohamed, Ahmed, Joos, Guy, Lahousse, Lies, Maes, Tania   +4 more
core   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

, 2013
Peer reviewedPublisher ...
Bickham U.R., Duval E., Fadok V.A., Fadok V.A., Gaipl U.S., Hart S.P., Luttmann W., Meagher L.C., Schwartz B.R., Walsh G.M.   +9 more
core   +3 more sources

Transcriptomics reveals new regulatory mechanisms involved in benralizumab response [PDF]

, 2023
[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge.
Dávila González, Ignacio Jesús, Estravís Sastre, Miguel, García Sánchez, María Asunción, Gil Melcón, María, Gómez‐García, Manuel, Isidoro García, María, Martín García, Cristina, Moreno‐Jimenez, Emma, Morgado, Natalia, Muñoz Bellido, Francisco Javier, Pérez Pazos, Jacqueline, Ramos González, Jacinto, Sanz Lozano, Catalina Sofía, Triviño, Juan Carlos   +13 more
core   +1 more source

Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]

, 2012
Peer reviewedPublisher ...
Walsh, Garry M.
core   +2 more sources

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source

Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]

, 2014
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core   +1 more source

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study

Journal of Clinical Medicine, 2023
Introduction: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking.
R. Campisi, S. Nolasco, C. Pelaia, P. Impellizzeri, M. D’Amato, Andrea Portacci, L. Ricciardi, G. Scioscia, N. Crimi, N. Scichilone, M. F. Foschino Barbaro, G. Pelaia, G. E. Carpagnano, A. Vatrella, C. Crimi   +14 more
semanticscholar   +1 more source

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma [PDF]

ERJ Open Research, 2021
Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.
Lawrence Mbuagbaw, Karissa Johnston, Niroshan Sriskandarajah, Stephen G Noorduyn, Stephen G Noorduyn, K Osenenko, A Gendron   +6 more
openaire   +4 more sources

Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics

ERJ Open Research, 2023
Background Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response.
Johannes A. Kroes, Kim de Jong, Simone Hashimoto, Sander W. Zielhuis, Eric N. van Roon, Jacob K. Sont, Anneke ten Brinke   +6 more
doaj   +1 more source

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

Frontiers in Medicine, 2022
BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of ...
Cristiano Caruso, Paolo Cameli, Elena Altieri, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Giorgio Walter Canonica, Stefano Centanni, Maria D’Amato, Stefano Del Giacco, Fausto De Michele, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Marco Caminati, Marco Caminati, Alessandra Vultaggio, Alessandro Zullo, Sara Rizzoli, Silvia Boarino, Gianfranco Vitiello, Francesco Menzella, Fabiano Di Marco   +27 more
doaj   +1 more source